Rolling out ~5-year overall survival results for frontline DARZALEX® + Rd triplet treatment1


Primary progression-free survival results from the MAIA trial, as well as a subgroup and post hoc analysis


Administration options include intravenous DARZALEX® and subcutaneous DARZALEX FASPRO®1,2*

At ~5 years: 32% reduction in the risk of death with DRd vs Rd alone in the MAIA trial (HR=0.68; 95% CI: 0.53, 0.86; P=0.0013; mOS not reached in either arm).1

*DARZALEX FASPRO® is administered by subcutaneous injection over approximately 3 to 5 minutes. In contrast, DARZALEX® is administered by intravenous infusion over approximately 7, 4, and 3 hours for first, second, and subsequent infusions, respectively.1,2 View IV administration

Median follow-up was 56 months in the DRd group (range: 53.0-60.1 months) and in the Rd group (range: 52.5-59.4 months).1,3

CI=confidence interval; DRd=DARZALEX® (D) + lenalidomide (R) + dexamethasone (d); HR=hazard ratio; IV=intravenous; mOS=median overall survival; Rd=lenalidomide (R) + dexamethasone (d); SC=subcutaneous.